Incidence of treatment-emergent adverse events in Parkinson’s disease patients according to baseline dopamine agonist use: post-hoc analysis from double-blind combined BIPARK-I and II data
Objective: To evaluate the incidence of treatment-emergent adverse events (TEAEs) in levodopa-treated Parkinson’s disease (PD) patients with motor fluctuations and taking opicapone (OPC). Background: OPC…A Phase 2 Dose Escalation Study of Ampreloxetine (TD-9855), a Norepinephrine Reuptake Inhibitor, Given Once-Daily to Treat Neurogenic Orthostatic Hypotension (nOH) in Subjects with Synucleinopathies
Objective: To assess the acute effects of ampreloxetine on the pressor response, improvement of symptoms and safety in a daily, single, escalating doses. Background: nOH…Population Pharmacokinetics and Pharmacodynamics of Ampreloxetine (TD-9855) in Patients with Neurogenic Orthostatic Hypotension (nOH)
Objective: To characterize the Phase 2 pharmacokinetics (PK) and pharmacodynamics (PD) of ampreloxetine in patients with nOH and provide dosing recommendations for special populations in…Rivastigmine for visual hallucinations in Parkinson’s disease
Objective: The aim of the study is to investigate whether early rivastigmine treatment of visual hallucinations in patients with Parkinson's disease delays the progression of…First year of Opicapone for Advanced Parkinson Disease: real-life experience in a single Movement Disorders Unit
Objective: The aim of the study is to evaluate opicapone in an heterogeneous patient population, reflecting daily clinical practice. Background: Opicapone is a new COMT-inhibitor indicated…Symptomatic treatment of hereditary spastic paraplegias with fampridine: a pilot study
Objective: Study the effect of fampridine in gait outcomes in patients with hereditary spastic paraplegia (HSP). Background: Fampridine acts through blockade of voltage-gated potassium channels,…The Effects of Apomorphine infusion on Head ptosis, a case report
Objective: Sustained Effects of Apomorphine infusion on Head Ptosis, a case report Background: IntroductionHead ptosis (Hp) results from weakness of the neck extensor, or increased…Botulinum toxin type A therapy in a movement disorders unit: a 23-year experience.
Objective: To update the experience with botulinum toxin type A therapy at the Unidad de Movimientos Involuntarios (UMI) of Instituto Nacional de Ciencias Neurologicas (INCN)-Lima,…Kinematic Gait Analysis in patients with ataxic disorders
Objective: To assess the kinematic gait parameters in patients with ataxia using gait analysis product “GAITRite”. Background: Ataxia is a disorder of balance and coordination…Onset symptoms and time to diagnosis in Friedreich´s Ataxia
Objective: In the present study, we aimed at analyzing onset symptoms in Friedreich Ataxia on the basis of natural history data from the EFACTS registry…
- « Previous Page
- 1
- …
- 11
- 12
- 13
- 14
- 15
- …
- 217
- Next Page »